Antimessenger oligonucleotide against urokinase receptor
US5872106A · kind A · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 1997 |
| Grant date | Feb 16, 1999 |
| Priority date | — |
| Expiry date | Feb 27, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense oligonucleotides optionally stabilized with phosphorotioate residues or analogues, or modified in the whole sugar-phosphate backbone--complementary to the human urokinase receptor messenger RNA--are able to prevent invasiveness of neoplastic cells by inhibiting the overexpression of the receptor itself, directly responsible of the invasive phenotype. Said oligomers are useful as medicaments for the treatment of primary and secondary neoplasias as well as of other pathologies wherein the urokinase receptor gene overexpression is a pathogenic event.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.